Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT) Following CE Mark news
Tweet Send to a Friend
Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $134.00 price target on Abbott Labs (NYSE: ABT) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
